PACB vs. QTRX, CTKB, LAB, AKYA, HBIO, BNGO, AXDX, OLK, MGNX, and ORIC
Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include Quanterix (QTRX), Cytek Biosciences (CTKB), Standard BioTools (LAB), Akoya Biosciences (AKYA), Harvard Bioscience (HBIO), Bionano Genomics (BNGO), Accelerate Diagnostics (AXDX), Olink Holding AB (publ) (OLK), MacroGenics (MGNX), and ORIC Pharmaceuticals (ORIC).
Pacific Biosciences of California (NASDAQ:PACB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Pacific Biosciences of California received 175 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 67.95% of users gave Pacific Biosciences of California an outperform vote while only 61.57% of users gave Quanterix an outperform vote.
86.5% of Quanterix shares are owned by institutional investors. 1.9% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 6.8% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Quanterix has a net margin of -26.42% compared to Pacific Biosciences of California's net margin of -152.97%. Quanterix's return on equity of -9.15% beat Pacific Biosciences of California's return on equity.
Pacific Biosciences of California presently has a consensus target price of $11.90, indicating a potential upside of 219.89%. Quanterix has a consensus target price of $32.00, indicating a potential upside of 39.56%. Given Pacific Biosciences of California's higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Quanterix.
Quanterix has lower revenue, but higher earnings than Pacific Biosciences of California. Quanterix is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Pacific Biosciences of California has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.
In the previous week, Pacific Biosciences of California had 1 more articles in the media than Quanterix. MarketBeat recorded 9 mentions for Pacific Biosciences of California and 8 mentions for Quanterix. Quanterix's average media sentiment score of 0.96 beat Pacific Biosciences of California's score of 0.51 indicating that Quanterix is being referred to more favorably in the news media.
Summary
Quanterix beats Pacific Biosciences of California on 11 of the 19 factors compared between the two stocks.
Get Pacific Biosciences of California News Delivered to You Automatically
Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Pacific Biosciences of California Competitors List
Related Companies and Tools